Key Highlights

  • The company held USD 498.5 million of cash, cash equivalents and short-term marketable Debt securities on September 30, 2026, which it says funds operations to mid-2028.
  • The third-quarter net loss was USD 79.5 million, or USD 0.93 per share, compared with USD 70.7 million, or USD 1.10 per share, a year earlier.
  • Research and development expense rose 13.6% to USD 68.9 million, including a USD 17.0 million increase in accrued regulatory milestone fees tied to the expected BLA acceptance.
  • Net cash used in Operating Activities for nine months was USD 185.2 million, against USD 137.2 million in the same period of 2025.

BLA Submission for SLK in Hidradenitis Suppurativa

MoonLake Immunotherapeutics (NASDAQ:MLTX) filed its 10-Q for the quarter ended September 30, 2026 on November 4, 2026. The clinical-stage company is a single-asset Business developing SLK, a tri-specific Nanobody that blocks IL-17A and IL-17F, for inflammatory skin and joint disease. On September 30, 2026 it submitted a Biologics License Application to the FDA for moderate-to-severe hidradenitis suppurativa in patients 12 and older. The company expects notice of acceptance within about 60 days of submission and the planned review timeline within about 74 days. Week 52 data from the VELA program showed 67.2% of patients reaching HiSCR75 and 33.1% reaching HiSCR100.

Loss Widens in Dollars but Narrows Per Share After Share Count Rises

Operating expenses were USD 79.9 million against USD 71.4 million, with Research and Development at USD 68.9 million and general and administrative at USD 11.0 million. The R&D rise includes USD 17.0 million of accrued milestone license fees owed to MHKDG on expected BLA acceptance and USD 2.8 million for Manufacturing of pre-launch inventory. The net loss grew 12.5%, yet the loss per share fell to USD 0.93 because weighted shares rose to 85.4 million from 63.4 million. Nine-month net loss per share was USD 2.74 against USD 2.61. The company has no product Revenue and expects operating losses for at least the next two years.

Psoriatic Arthritis Data, Next Trial Readouts and Funding Risk

In August 2026 the company reported that the IZAR-1 psoriatic arthritis trial met all week 16 endpoints, with 42.1% of biologic-naive patients on the 60 mg dose with induction reaching ACR50. Comparisons against placebo remain blinded. Enrollment in IZAR-2 was completed in September, with initial topline results expected in the first quarter of 2027, and the adolescent VELA-TEEN final topline is also expected in that quarter. The filing notes that cross-trial comparisons are not head-to-head. Long-term debt was USD 100.0 million, and the pre-launch spending needed for a commercial rollout, plus any FDA delay or rejection, remain the main risks.

Where Things Stand

The cash buys time through mid-2028 on the company's current operating plan, covering regulatory review and launch preparation for its only asset. MoonLake Immunotherapeutics (NASDAQ:MLTX) is spending roughly USD 62 million a quarter in operating cash on a nine-month average (calculated) while holding USD 100.0 million of long-term debt, so the runway depends on the FDA path. The filing gives no market reaction. Next markers are the FDA decision on accepting the BLA, expected within about 60 days of September 30, the planned review timeline, the November start of the Phase 3 NOVA trial and first-quarter 2027 trial results.